Bone and joint infections are devastating afflictions. Although medical interventions and
advents have improved their care, bone and joint infections still portend dismal outcomes …

Treatment of serious gram‐positive infections presents multiple challenges. Treatment often
results in prolonged hospitalization for administration of intravenous antimicrobials and …

Background Long-acting lipoglycopeptides (laLGPs) are FDA approved only for acute
bacterial skin and skin structure infections (ABSSSIs). However, these antibiotics show …

Infections associated with orthopaedic implants represent a major health concern
characterized by a remarkable incidence of morbidity and mortality. The wide variety of …

Background: There is increasing interest in the use of oritavancin and dalbavancin for
complicated Gram-positive infections as an alternative to in-hospital intravenous or …

Oritavancin is a long-acting lipoglycopeptide with in vitro activity against Gram-positive
pathogens, as well as good bactericidal activity and sterilisation ability in biofilm. It has been …

Background Acute osteomyelitis is typically caused by Gram-positive pathogens, commonly
antibiotic-resistant Staphylococcus species. Standard antibiotic treatment is challenging due …

Background Oritavancin (ORI) is a long-acting lipoglycopeptide indicated for the treatment of
adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or …

Osteomyelitis remains difficult to treat, typically requiring a prolonged course of intravenous
(iv) antibiotics. The optimal route and duration of antibiotics remains ill-defined due to limited …

Osteomyelitis is a difficult-to-treat disease that can require both surgical debridement and a
prolonged course of antimicrobial therapy. Current standard of care for the antimicrobial …